Miscellaneous Photography/iStock Editorial via Getty Images
biomarin (NASDAQ: BMRN) said it plans to focus on commercializing its hemophilia A therapy Roctavian in the United States, Germany and Italy, with the goal of making the product profitable by the end of 2025.
The biotech company noted that Roctavian It is approved and reimbursed in these three markets for the treatment of severe hemophilia A. according to a statement.
BioMarin expects the move to reduce direct costs for Roctavian by approximately $60 million per year starting in 2025.
The company added that it has placed its gene therapy manufacturing facility on idle until additional production is required. It will stop enrolling new patients in its clinical development program but will support those already receiving treatment.
BioMarin also released its second-quarter earnings report on Monday and raised its 2024 financial guidance.
